ERBB2 and neoplasm: In the matched cohorts, the prognostic factors of the clinical stage, pathological stage, and tumor markers of the HR status, HER2 status, and histological grade were balanced between the group of TTR ≤10 weeks (N=95) and group of TTR of 10–20 weeks (N=95) and between the group of TTR >20 weeks (N=36) and the group of TTR of 10–20 weeks (N=36) (Table S1).